Subgroup outcome | No. of comparisons | No. of subjects || | Treatment effect on TC (mmol/L) ¶ | Heterogeneity p-value § |
---|---|---|---|---|
Form of intervention †: |  |  |  |  |
   a.) isoflavones tablets | 482 | 0.01 (-0.17, 0.18) | 1.00 | |
   b.) ISP(+) | 229 | -0.11 (-0.21, -0.01)* | 0.34 | |
   c.) soy protein capsule | 1 [11] | 78 | -0.69 (-1.19, -0.19)* | NA |
   d.) soy biscuit | 1 [7] | 20 | -0.05 (-0.47, 0.37) | NA |
   e.) soy burger | 1 [19] | 44 | 0.09 (-0.38, 0.56) | NA |
   f.) Overall | 853 | -0.09 (-0.18, -0.01)* | 0.77 | |
Isoflavones mixture ‡: |  |  |  |  |
   G&D&B&F | 214 | -0.06 (-0.34, 0.21) | 0.96 | |
   G&D | 285 | -0.22 (-0.41, -0.03)* | 0.06 | |
   G | 1 [21] | 60 | 0.10 (-0.35, 0.55) | NA |
Isoflavones intake (mg per day): | Â | Â | Â | Â |
   < 50 | 132 | -0.12 (-0.54, 0.29) | 0.99 | |
   51–100 | 484 | -0.10 (-0.21,0.01) | 0.74 | |
   101 – 150 | 176 | -0.10 (-0.24, 0.05) | 0.09 | |
Design : | Â | Â | Â | Â |
   parallel crossover | 447 | -0.08 (-0.27, 0.10) | 0.48 | |
a.) no washout | 1 [22] | 56 | -0.43 (-0.73, -0.13)* | NA |
b.) washout mentioned | 208 | -0.07 (-0.17, 0.03) | 0.91 | |
Gender: | Â | Â | Â | Â |
   male | 76 | -0.30 (-0.54, -0.05)* | 0.15 | |
   female | 674 | -0.07 (-0.17, 0.02) | 0.89 | |
Treatment length: | Â | Â | Â | Â |
   2–10 weeks | 541 | -0.09 (-0.18, 0.00) | 0.84 | |
   11–20 weeks | 155 | -0.22 (-0.52, 0.07) | 0.07 | |
   21–30 weeks | 157 | 0.02 (-0.28, 0.31) | 0.96 | |
Menopausal status: | Â | Â | Â | Â |
   pre-menopausal | 80 | -0.06 (-0.17, 0.06) | 0.58 | |
   peri-menopausal | 1 [11] | 78 | -0.69 (-1.19, -0.19)* | NA |
   post-menopausal | 516 | -0.05 (-0.20, 0.10) | 1.00 | |
Subjects with: | Â | Â | Â | Â |
   normolipidemia | 377 | -0.11 (-0.21, -0.01)* | 0.08 | |
   hyperlipidemia | 105 | -0.05 (-0.36, 0.26) | 1.00 |